RT Journal Article
SR Electronic
T1 SARS-CoV-2 testing in the Slovak Republic from March 2020 to September 2022 – summary of the pandemic trends
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.26.23291891
DO 10.1101/2023.06.26.23291891
A1 Janostiakova, Nikola
A1 Gnip, Andrej
A1 Kodada, Dominik
A1 Saade, Rami
A1 Blandova, Gabriela
A1 Mikova, Emilia
A1 Tibenska, Elena
A1 Repiska, Vanda
A1 Minarik, Gabriel
YR 2023
UL http://medrxiv.org/content/early/2023/06/28/2023.06.26.23291891.abstract
AB The COVID-19 pandemic has been part of Slovakia since March 2020. Intensive laboratory testing ended in October 2022, when the number of tests dropped significantly, but the state of the pandemic continues to this day. For the management of COVID-19, it is important to find an indicator that can predict pandemic changes in the community. The average daily/weekly Ct value with a certain time delay can predict changes in the number of cases of SARS-CoV-2 infection, which can be a useful indicator for the healthcare system. The study analyzed the results of 1,420,572 RT-qPCR tests provided by one accredited laboratory during the ongoing pandemic in Slovakia from March 2020 to September 2022. The total positivity of the analyzed tests was 24.64%. The average Ct values found were the highest in the age group of 3-5 years, equal to the number 30.75; the lowest were in the age group > 65 years, equal to the number 27. The average weekly Ct values ranged from 22.33 (pandemic wave week) to 30.12 (summer week). We have summarized the results of SARS-CoV-2 diagnostic testing in Slovakia with the scope defined by the rate and positivity of tests carried out at Medirex a.s. laboratories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the OPII program as the project - Research on COVID-19 progressive diagnostic methods and biomarkers useful in early detection of individuals at increased risk of severe disease, ITMS: 313011ATA2, co-financed by the ERDF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethical committee of Bratislava Self-Governing District under the identifier 03228/2021/HF from January 12, 2021. All patients have filled the questionnaires with relevant information regarding their health status in relation to COVID-19 and signed informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors